溶瘤病毒在脑胶质瘤治疗中的研究进展

Advances in oncolytic virotherapy for glioma

近年来,溶瘤病毒在脑胶质瘤治疗中的应用成为研究热点,关于溶瘤病毒的改造、疗效和安全性等临床研究结果的发布,使脑胶质瘤治疗的发展前景充满希望。目前,由单纯疱疹病毒改造的溶瘤病毒在日本已获得批准用于治疗恶性脑胶质瘤,为脑胶质瘤的临床治疗带来了新模式。重组脊髓灰质炎病毒、腺病毒联合免疫检查点抑制剂治疗脑胶质瘤的临床试验结果均获得了良好的生存结果。同时,溶瘤病毒治疗过程中也存在给药途径的选择和治疗效果的持续性等问题,尚需进一步的基础和临床研究来提高和优化溶瘤病毒用于脑胶质瘤的疗效和治疗策略。

In recent years,there has been significant progress in the research of oncolytic viruses for the therapy of gliomas.The latest clinical trial results related to the modification,effectiveness,and safety of oncolytic viruses have brought hope for the development of glioblastoma treatments.Modified oncolytic viruses,particularly those based on the herpes simplex virus,have gained approval in Japan.Clinical trials involving recombinant poliovirus have shown better-than-expected survival outcomes with a strong safety profile.Notably,the first-time report of adenovirus in combination with immune checkpoint inhibitors for glioblastoma has demonstrated promising survival benefits and safety.However,challenges remain,including the selection of administration routes and the sustainability of treatment effects during oncolytic virus therapy.Therefore,further preclinical and clinical studies are required to improve the effectiveness and optimize treatment strategy for glioblastoma using oncolytic viruses.